Skip to content

Study · Not a test of the peptide alone · 2005

2 results

Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH

The Journal of clinical endocrinology and metabolism21 Dec 2004Cited by 92 (Europe PMC)

PMID15613428 (opens in a new tab)DOI10.1210/jc.2004-0826 (opens in a new tab)PepBankPUB-15613428
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women with osteoporosis receiving teriparatide, vertebral fracture risk did not significantly increase across prior-fracture subgroups.

    In plain wordsIn women receiving teriparatide, vertebral fracture risk did not significantly increase across prior-fracture subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVertebral fracture risk across prior-fracture subgroups
    Study

    n: not reported in source

    Comparator
    Other prior-fracture subgroups within teriparatide arm
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups.
    2 context sentences
    Summary · context
    The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 mug) in the Fracture Prevention Trial.
    Summary · context
    The median observation time was 21 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women with osteoporosis receiving teriparatide, nonvertebral fracture risk did not significantly increase across prior-fracture subgroups.

    In plain wordsIn women receiving teriparatide, nonvertebral fracture risk did not significantly increase across prior-fracture subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNonvertebral fracture risk across prior-fracture subgroups
    Study

    n: not reported in source

    Comparator
    Other prior-fracture subgroups within teriparatide arm
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups.
    2 context sentences
    Summary · context
    The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 mug) in the Fracture Prevention Trial.
    Summary · context
    The median observation time was 21 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.